Trigger-happy AstraZeneca (AZN -0.95%) is done waiting for home-grown talent to develop. In recent weeks, the Big Pharma laggard has acquired Omthera (NASDAQ: OMTH) and Pearl Therapeutics. These acquisitions instantly inject one promising late-stage drug into the  pipeline, one drug facing regulatory approval into the product mix, and a few others in earlier stages of development. The company has thrust itself into competing in two major markets virtually overnight. This is certainly a welcomed sight for investors, who have experienced their fair share of disappointment in recent quarters. The moves don't put AstraZeneca on the same level as more successful peers, but it is a great start to getting back on the right track. In the following video, Fool contributor Maxx Chatsko explains what the moves mean for investors.